Insights › Likitanci da magunguna › November 13, 2026
Likitanci da magunguna · Bayanan hukuma

EMA ta ba da shawarar amincewa da Zybrivo (sintilimab) don NSCLC

European Union EMA (New human medicines) An wallafa:

A ranar 12 ga Nuwamba 2026, Kwamitin CHMP na EMA ya amince da ra'ayi mai kyau yana ba da shawarar izinin talla don Zybrivo (sintilimab). Mai nema Fortvita yana neman amincewa da wannan magani don magance non-squamous non-small cell lung cancer a cikin manya. Wannan yana faɗaɗa zaɓuɓɓukan rigakafi don wannan takamaiman nau'in ciwon daji.

Asalin tushe
Karanta tushen — ema.europa.eu ↗

Muna haɗawa da ainihin mai wallafawa. Taƙaitawar da ke sama jagora ce kawai; karanta asalin don cikakken bayani.

Ƙari a Likitanci da magunguna

Duba komai a cikin Likitanci da magunguna →

Ƙara bincika wannan batu

Karanta kowane bayani da yarenka

Wannan shafi yana nuna sabbin abubuwa uku ne kawai a kowane fanni. Mambobi na ganin kowane bayani a cikin fannin, a harsuna 109, tare da injinan bincike da ke aiki a kansu.

Karanta duka — fara daga $3Babu buƙatar shigarwa daga kantin manhajoji. Ana iya soke shi kowane lokaci.